PARP1 and head and neck squamous cell carcinoma: Multiple PARP inhibitors (PARPis; singular: PARPi) have already been market-approved in different gynecological tumor entities [42,43,44,45,46,47], and preclinical evidence indicates the radiosensitizing effects of PARPis in HNSCC as well [48,49,50,51,52].